Efficacy of Risperidone in Managing Maladaptive Behaviors for Children With Autistic Spectrum Disorder: A Meta-Analysis

Journal of Pediatric Health Care

Volumn 26, Issue 4, 2012, Pages 291-299

  Sharma, Akanksha ^a   Shaw, Steven R ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Atypical antipsychotics; Autism; Autism spectrum disorder; Developmental disabilities; Pervasive developmental disorder; Risperidone

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ARTICLE; AUTISM; BEHAVIOR DISORDER; CHILD; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; META ANALYSIS; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD BEHAVIOR DISORDERS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; RISPERIDONE; TREATMENT OUTCOME;

EID: 84862690094     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedhc.2011.02.008     Document Type: Article

References (71)

1. Aman M.G., Arnold L.E., McDougle C.J., Vitiello B., Scahill L., Davis M., Lindsay R.L., et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology 2005, 15:869-884.
2. Aman M.G., Hollway J., McDougle C., Scahill L., Tierney E., McCracken J.T., Posey D.J., et al. Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology 2008, 18:227-236.
3. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed.
4. Anderson L.T., Campbell M., Grega D.M., Perry R., Small A.M., Green W.H. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry 1984, 141:1195-1202.
5. Barnard L., Young A.H., Pearson J., Geddes J., O'Brien G. A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology 2002, 16:93-101.
6. Campbell M., Armenteros J.L., Malone R.P., Adams P.B., Eisenberg Z.W., Overall J.E. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academic of Child and Adolescent Psychiatry 1997, 36:835-843.
7. Canitano R. Self injurious behavior in autism: Clinical aspects and treatment with risperidone. Journal of Neurotransmission 2006, 113:425-431.
8. Capone G.T., Goyal P., Grados M., Smith B., Kammann H. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study. Journal of Developmental and Behavioral Pediatrics 2008, 29:106-116.
9. Calarge C.A., Acion L., Kuperman S., Tansey M., Schlechte J.A. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2009, 19:101-109.
10. Chavez B., Chavez-Brown M., Sopko M.A., Rey J.A. Atypical antipsychotics in children with pervasive developmental disorders. Pediatric Drugs 2007, 9:249-266.
11. Cohen J. A power primer. Psychological Bulletin 1992, 112:155-159.
12. Cohen I.L., Campbell M., Posner D., Small A.M., Triebel D., Anderson L.T. Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. Journal of the American Academy of Child and Adolescent Psychiatry 1980, 19:665-667.
13. Collins F.L. One year post-exclusivity adverse event review: Risperidone (Pediatric Advisory Committee Meeting) 2008 November 18, U.S. Food and Drug Administration, Washington, DC.
14. Correll C.U. Antipsychotic use in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry 2008, 47:9-20.
15. Diler R.S., Firat S., Avci A. An open label trial of risperidone in children with autism. Current Therapeutic Research and Clinical Experience 2002, 63:91-102.
16. Elias, M. (2006, May 2). Adult antipsychotics can worsen troubles. USA Today.
17. Elvins R., Green J. Pharmacological management of core and comorbid symptoms in autism-spectrum disorder. Advances of Psychiatric Treatment 2010, 16:349-360.
18. Erickson C.A., Stigler K.A., Posey D.J., McDougle C.J. Risperidone in pervasive developmental disorders. Expert Review of Neurotherapeutics 2005, 5:713-719.
19. Eugene A.L., Vitiello B., McDougle C., Scahill L., Shah B., Gonzalez N., Tierney E., et al. Parent-defined target symptoms respond to risperidone in RUPP Autism Study: Customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:1443-1450.
20. Fleischhaker C., Heiser P., Henninghausen K., Herpertz-Dahlman B., Holtkamp K., Mehler-Wex C., Warnke A., et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine, and risperidone. Journal of Neural Transmission 2008, 115:1599-1608.
21. Fombonne E. Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents. Evidence Based Mental Health 2006, 9. 6.
22. Gagliano A., Germano E., Pustorino G., Impallomeni C., D'Arrigo C., Calamoneri F., Spina E., et al. Risperidone treatment of children with autistic spectrum disorder: Effectiveness, tolerability and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology 2004, 14:39-47.
23. Gencer O.F., Neslihan I.E., Miral S., Baykara B., Baykara A., Dirik E. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. European Child and Adolescent Psychiatry 2008, 17:217-225.
24. Harrison-Woolruch M., Garcia-Quiroga J., Ashton J., Herbison P. Safety and usage of atypical medicines in children. Drug Safety 2007, 30:569-579.
25. Heykants J., Huang M.L., Mannens G., Meuldermans W., Snoeck E., Van Beijsterveldt L. The pharmaco-kinetics of risperidone in humans: A summary. Journal of Clinical Psychiatry 1994, 55:13-17.
26. Horner R.H., Carr E.G., Strain P.S., Todd A.W., Reed H.K. Problem behavior interventions for young children with autism: A research synthesis. Journal of Autism and Developmental Disorders 2002, 32:423-446.
27. Horrigan J.P., Barnhill L.J. Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorders 1997, 27:313-323.
28. James A.C. Prescribing antipsychotics for children and adolescents. Pediatrics 2009, 124:1533-1540.
29. Jerrell J.M., McIntyre R.S. Adverse events in children and adolescents treated with antipsychotic medications. Human Psychopharmacology: Clinical and Experimental 2008, 23:283-290.
30. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry 2001, 158:360-369.
31. Kuroki T., Nagao N., Nakaha T. Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. Progress in Brain Research 2008, 172:199-212.
32. Kuehn B.M. FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. Journal of the American Medical Association 2009, 302:833-834.
33. Kwon H. Tardive dyskinesia in an autistic patient treated with risperidone. American Journal of Psychiatry 2004, 161:757-758.
34. Lilienfeld S.O. Scientifically unsupported and supported interventions for childhood psychopathology: A summary. Pediatrics 2005, 115:761-764.
35. Luby J., Mrakotsky C., Stalets M.M., Belden A., Heffelfinger A., Williams M., Spitznagel E., et al. Risperidone in preschool children with autism spectrum disorders: An investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology 2006, 16:575-587.
36. Malone R.P. Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-based Mental Health 2006, 9:56-66.
37. Malone R.P., Maislin G., Choudhury M.S., Gifford C., Delaney M.A. Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:140-147.
38. Mandoki M.W. Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects?. Journal of Child and Adolescent Psychopharmacology 1995, 5:49-67.
39. Masi G., Cosenza A., Mucci M., Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. Journal of the American Academy of Children and Adolescent Psychiatry 2001, 40:1206-1214.
40. Masi G., Cosenza A., Mucci M., De Vito G. Risperidone monotherapy in preschool children with pervasive developmental disorders. Journal of Child Neurology 2001, 16:395-400.
41. Masi G.M., Cosenza A., Mucci M., Brovedani P. A 3-year naturalistic study of preschool children with pervasive developmental disorders treated with risperidone. Journal of Clinical Psychiatry 2003, 64:1039-1047.
42. Matson J.L., Dempsey T. Autism spectrum disorders: Pharmacotherapy for challenging behaviors. Journal of Developmental and Physical Disabilities 2008, 20:175-191.
43. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., McMahon D., et al. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 2002, 347:314-321.
44. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., Vitiello B., et al. Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry 2005, 162:1142-1148.
45. McNally P., McNichols F., Oslizlok P. The QT interval and psychotropic medications in children. European Child and Adolescent Psychiatry 2006, 16:33-47.
46. Miral S., Gender O.F., Inal-Emiroglu N., Bayakara B., Bayakara A., Dirik E. Risperidone versus haloperidol in children and adolescents with AD. European Child and Adolescent Psychiatry 2008, 17:1-8.
47. Mukaddes N., Abali O., Gurkan K. Short-term efficacy and safety of risperidone in young children with autistic disorder (AD). World Journal of Biological Psychiatry 2004, 5:211-214.
48. Nagaraj R., Singhi P., Malhi P. Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. Journal of Child Neurology 2006, 21:450-455.
49. Owen R., Sikich L., Marcus R.N., Corey-Lisle P., Manos G., McQuade R.D., Findling R.L., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
50. Pandina G.J., Bossie C.A., Youssef E., Zhu Y., Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders 2007, 37:367-373.
51. Pennington B.F., Ozonoff S. Executive functions and developmental psychopathology. Journal of Child Psychology and Psychiatry 1996, 37:51-87.
52. Ratzoni G., Gothelf D., Brand-Gothelf A., Reidman J., Kikinzon L., Gal G., Weizman R., et al. Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academic of Child & Adolescent Psychiatry 2002, 41:337-343.
53. Research Units on Pediatric Psychopharmacology Autism Network Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry 2005, 162:1361-1369.
54. Scahill L., Aman M.G., McDougle C.J., Arnold L.E., McCracken J.T., Handen B., Sukhodolsky D., et al. Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders 2008, 39:720-729.
55. Seeman P. Atypical antipsychotics: Mechanism of action. Focus 2004, 2:48-58.
56. 2 atypical antipsychotics. American Journal of Psychiatry 2005, 162:1984-1985.
57. Shaw S.R., Bruce J., Sharma A., Ouimet T., Glaser S. Children with autistic spectrum disorders and atypical anti-psychotic medications: Debate, differences and dual diagnosis. Journal of Early Childhood and Infant Psychology 2009, 5:37-55.
58. Shaw S.R., Dawkins T. Atypical antipsychotics and autism. Psychiatric disorders: Current topics and interventions for educators 2010, 50-59. CA: Sage/Corwin Press, Thousand Oaks. P. McCabe, S.R. Shaw (Eds.).
59. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641.
60. Stachnik J.M., Nunn-Thompson C. Use of atypical antipsychotics in the treatment of autistic disorder. Annals of Pharmacotherapy 2007, 41:626-634.
61. Troost P.W., Lahuis B.E., Steenhuis M.P., Ketelaars C.E.J., Buitelaar J.K., Engeland H.V., Hoekstra P.J., et al. Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:1137-1144.
62. Tyrer P., Kendall T. The spurious advance of antipsychotic drug therapy. The Lancet 2009, 373:4-5.
63. Varley C., McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. Journal of the American Medical Association 2009, 302:1811-1812.
64. Weiss M.J., Harris S.L. Teaching social skills to people with autism. Behavioral Modification 2001, 25:785-802.
65. West L., Waldrop J. Risperidone use in the treatment of behavioural symptoms in children with autism. Pediatric Nursing 2006, 32:545-549.
66. Wetterling T., Mubigbrodt H.E. Weight gain: Side effects of atypical neuroleptics?. Journal of Clinical Psychopharmacology 1999, 19:316-321.
67. Williams S.K., Scahill L., Vitiellio B., Aman M.G., Arnold L.E., McDougle C.J., Sparrow S., et al. Risperidone and adaptive behavior in children with autism. Journal of American Academy of Child and Adolescent Psychiatry 2006, 45:431-439.
68. Witwer A., Lecavelier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology 2005, 15:671-681.
69. Wonodi I., Reeves G., Carmichael D., Verosky I., Avila M.T., Elliot A., Thaker G.K., et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Movement Disorders 2007, 22:1777-1782.
70. Yan J. Risperidone approved to treat schizophrenia in children. American Psychiatric News 2007, 42:18.
71. Zuddas A., Di Martino A., Muglia P., Cianchetti C. Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation. Journal of Child and Adolescent Psychopharmacology 2002, 10:79-90.